The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Changes in Bone Mineral Density, Body Composition, and Lipid Metabolism during Growth Hormone (GH) Treatment in Children with GH Deficiency1
Abstract
Adults with childhood onset GH deficiency (GHD) have reduced bone mass, increased fat mass, and disorders of lipid metabolism. The aim of the present study was to evaluate bone mineral density (BMD), bone metabolism, body composition, and lipid metabolism in GHD children before and during 2-3 yr of GH treatment (GHRx). Forty children with GHD, mean age 7.9 yr, participated in the study of bone metabolism and body composition; and an additional group of 17 GHD children, in the study of lipid metabolism. Lumbar spine BMD, total body BMD, and body composition were measured with dual-energy x-ray absorptiometry. Volumetric BMD (bone mineral apparent density, BMAD) was calculated to correct for bone size. BMD, BMAD, lean tissue mass, bone mineral content, fat mass, and percentage body fat were expressed as SD scores (SDS), in comparison with normative data of the same population. Lumbar spine BMD and BMAD and total body BMD were all decreased at baseline. All BMD variables increased significantly during GHRx, lumbar spine BMD SDS, already after 6 months of treatment. Lean tissue mass SDS increased continuously. Bone mineral content SDS started to increase after 6 months GHRx. Fat mass SDS decreased during the first 6 months of GHRx and remained stable thereafter. Biochemical parameters of bone formation and bone resorption did not differ from normal at baseline and increased during the first 6 months of GHRx. Serum 1,25 dihydroxyvitamin D increased continuously during GHRx, whereas PTH and serum calcium remained stable. Lipid profile was normal at baseline: Atherogenic index had decreased and apolipoprotein A1(Apo-A1) had increased after 3 yr of treatment. In conclusion, children with GHD have decreased bone mass. BMD, together with height and lean tissue mass, increased during GHRx. GHRx had a beneficial effect on lipid metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical consequences of GHD may include reduced adult height, decreased lean body mass and muscle strength, reduced metabolic rate, increased abdominal fat, decreased quality of life (QOL), cognitive issues, and memory and attention deficits.25,68–71”
In the citing paper
“Treatment with GH can also improve bone mineral density, decrease fat mass, increase lean muscle mass, and improve cardiopulmonary functional capacity.69,71,101”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tanner, J. M., & Whitehouse, R. H. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.3.170 · Cited by 3,137
Cited by
The adolescent brain and age-related behavioral manifestations
Spear, L. P. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(00)00014-2 · Cited by 5,433
Grimberg, A., DiVall, S. A., Polychronakos, C., Allen, D. B., Cohen, L. E., Quintos, J. B., Rossi, W. C., Feudtner, C., Murad, M. H., & on behalf of the Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (2016) · Hormone Research in Paediatrics · doi:10.1159/000452150 · Cited by 697
Acquisition of optimal bone mass in childhood and adolescence
Bachrach, L. K. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(00)00336-2 · Cited by 422
van der Sluis, I. M. (2002) · Archives of Disease in Childhood · doi:10.1136/adc.87.4.341 · Cited by 362
Effect of GH/IGF-1 on Bone Metabolism and Osteoporsosis
Locatelli, V., & Bianchi, V. E. (2014) · International Journal of Endocrinology · doi:10.1155/2014/235060 · Cited by 307
Metadata
- Authors
- Boot, A. M., Engels, M. A. M. J., Boerma, G. J. M., Krenning, E. P., & de Muinck Keizer-Schrama, S. M. P. F.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1997-08
- Volume
- 82
- Issue
- 8
- Pages
- 2423-2428
- ISSN
- 0021-972X
- 1945-7197
- Cited by
- 11
- References
- 1
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.